SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-075684
Filing Date
2020-06-22
Accepted
2020-06-22 17:15:18
Documents
5
Period of Report
2020-08-03
Effectiveness Date
2020-06-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2021357-7_def14a.htm DEF 14A 588967
2 GRAPHIC tm2021357d7-pc1_votebw.jpg GRAPHIC 327472
3 GRAPHIC tm2021357d7-pc2_votebw.jpg GRAPHIC 241459
4 GRAPHIC lg_menlotherapeuticsnew-4c.jpg GRAPHIC 40555
5 GRAPHIC sg_daviddomzalski-bw.jpg GRAPHIC 1346
  Complete submission text file 0001104659-20-075684.txt   1431704
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
Menlo Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 20979572
SIC: 2834 Pharmaceutical Preparations